Cargando…
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action
BACKGROUND: There is increased recognition that incorporating patients’ perspectives and insights into the medicines development process results in better health outcomes and benefits for all involved stakeholders. Despite the increased interest and the existence of frameworks and practical recommen...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108434/ https://www.ncbi.nlm.nih.gov/pubmed/33970465 http://dx.doi.org/10.1007/s43441-021-00282-z |
_version_ | 1783690129522556928 |
---|---|
author | Cavaller-Bellaubi, Maria Faulkner, Stuart D. Teixeira, Bryan Boudes, Mathieu Molero, Eva Brooke, Nicholas McKeaveney, Laura Southerton, Jeffrey Vicente, Maria José Bertelsen, Neil García-Burgos, Juan Pirard, Vinciane Reid, Kirsty Ferrer, Elisa |
author_facet | Cavaller-Bellaubi, Maria Faulkner, Stuart D. Teixeira, Bryan Boudes, Mathieu Molero, Eva Brooke, Nicholas McKeaveney, Laura Southerton, Jeffrey Vicente, Maria José Bertelsen, Neil García-Burgos, Juan Pirard, Vinciane Reid, Kirsty Ferrer, Elisa |
author_sort | Cavaller-Bellaubi, Maria |
collection | PubMed |
description | BACKGROUND: There is increased recognition that incorporating patients’ perspectives and insights into the medicines development process results in better health outcomes and benefits for all involved stakeholders. Despite the increased interest and the existence of frameworks and practical recommendations, patient engagement (PE) is not yet considered standard practice. The objective of this work was to provide a roadmap to support systematic change in all stakeholder organisations involved in medicines development across Europe, patients and patient organisations, medicines developers, academia, regulatory authorities, Health Technology Assessment bodies, payers, policy-makers and public research funders, to sustain PE practices. METHODS: A mixed-methods approach was used by the EU-funded Innovative Medicines Initiative PARADIGM Consortium to co-develop the sustainability roadmap including background work to identify success factors and scenarios for sustainable PE. The roadmap development was based on the Theory of Change concept and populated with findings from (1) interviews with national/ and international institutions with the potential to increase PE uptake by other stakeholders; (2) multi-stakeholder workshops and webinars; and (3) consultations with specific stakeholder groups, Consortium members and a consultative body formed by international PE initiatives. RESULTS: This roadmap sets strategic goals for the PE community to achieve meaningful and systematic PE through changes in the culture, processes and resources of stakeholder organisations. It brings in key PARADIGM outputs to work in a coordinated fashion with existing frameworks and mechanisms to achieve system-wide sustained PE. CONCLUSIONS: The roadmap provides a framework for all stakeholders to take collective action within their organisations and across Europe to implement PE in a sustainable manner. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43441-021-00282-z. |
format | Online Article Text |
id | pubmed-8108434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-81084342021-05-11 Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action Cavaller-Bellaubi, Maria Faulkner, Stuart D. Teixeira, Bryan Boudes, Mathieu Molero, Eva Brooke, Nicholas McKeaveney, Laura Southerton, Jeffrey Vicente, Maria José Bertelsen, Neil García-Burgos, Juan Pirard, Vinciane Reid, Kirsty Ferrer, Elisa Ther Innov Regul Sci Original Research BACKGROUND: There is increased recognition that incorporating patients’ perspectives and insights into the medicines development process results in better health outcomes and benefits for all involved stakeholders. Despite the increased interest and the existence of frameworks and practical recommendations, patient engagement (PE) is not yet considered standard practice. The objective of this work was to provide a roadmap to support systematic change in all stakeholder organisations involved in medicines development across Europe, patients and patient organisations, medicines developers, academia, regulatory authorities, Health Technology Assessment bodies, payers, policy-makers and public research funders, to sustain PE practices. METHODS: A mixed-methods approach was used by the EU-funded Innovative Medicines Initiative PARADIGM Consortium to co-develop the sustainability roadmap including background work to identify success factors and scenarios for sustainable PE. The roadmap development was based on the Theory of Change concept and populated with findings from (1) interviews with national/ and international institutions with the potential to increase PE uptake by other stakeholders; (2) multi-stakeholder workshops and webinars; and (3) consultations with specific stakeholder groups, Consortium members and a consultative body formed by international PE initiatives. RESULTS: This roadmap sets strategic goals for the PE community to achieve meaningful and systematic PE through changes in the culture, processes and resources of stakeholder organisations. It brings in key PARADIGM outputs to work in a coordinated fashion with existing frameworks and mechanisms to achieve system-wide sustained PE. CONCLUSIONS: The roadmap provides a framework for all stakeholders to take collective action within their organisations and across Europe to implement PE in a sustainable manner. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43441-021-00282-z. Springer International Publishing 2021-05-10 2021 /pmc/articles/PMC8108434/ /pubmed/33970465 http://dx.doi.org/10.1007/s43441-021-00282-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Cavaller-Bellaubi, Maria Faulkner, Stuart D. Teixeira, Bryan Boudes, Mathieu Molero, Eva Brooke, Nicholas McKeaveney, Laura Southerton, Jeffrey Vicente, Maria José Bertelsen, Neil García-Burgos, Juan Pirard, Vinciane Reid, Kirsty Ferrer, Elisa Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title_full | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title_fullStr | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title_full_unstemmed | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title_short | Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action |
title_sort | sustaining meaningful patient engagement across the lifecycle of medicines: a roadmap for action |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108434/ https://www.ncbi.nlm.nih.gov/pubmed/33970465 http://dx.doi.org/10.1007/s43441-021-00282-z |
work_keys_str_mv | AT cavallerbellaubimaria sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT faulknerstuartd sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT teixeirabryan sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT boudesmathieu sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT moleroeva sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT brookenicholas sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT mckeaveneylaura sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT southertonjeffrey sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT vicentemariajose sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT bertelsenneil sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT garciaburgosjuan sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT pirardvinciane sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT reidkirsty sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction AT ferrerelisa sustainingmeaningfulpatientengagementacrossthelifecycleofmedicinesaroadmapforaction |